The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007.
Initial studies indicate that P2D’s lead compounds are as effective as current first-line ADHD treatments in preclinical ADHD models.
Additionally, preclinical studies indicate that P2D’s lead compounds demonstrate reduced side effects, the primary criticism of existing first-line treatments.
P2D CEO Frank Zemlan said they believe that the combination of P2D’s improved patent position and preclinical studies demonstrates efficacy and limited side effects places them to develop a novel safe and effective ADHD treatment.
In addition to the US and Canadian patents, patent protection for P2D’s family of ADHD compounds is being prosecuted internationally.